BioSpace News Archive

bluebird bio, Inc. announced that it received a notice on April 24, 2024 from The Nasdaq Stock Market LLC stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023, it is no longer in compliance with Nasdaq Listing Rule 5250, which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission.

Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 5,400 shares of its common stock under the Company’s 2023 Inducement Plan.

ReNAgade Therapeutics announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem.

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC).

Arbele today announced the positive recommendation from the second meeting of the Data Monitoring Committee (DMC) to continue the A001 Phase I clinical trial evaluating cabotamig (ARB202) in patients with advanced gastrointestinal (GI) cancers without modification to the trial protocol.

Ocugen, Inc. announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa, OCU410 for the treatment of geographic atrophy, and OCU410ST for the treatment of Stargardt disease at The Association for Research in Vision and Ophthalmology 2024 Annual Meeting in Seattle, WA from May 5-9, 2024.

Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for RAG-01.

PharmaLink Inc., a national leader in pharmaceutical reverse distribution, and Recall Results, a prominent provider of comprehensive recall management and support services, today announced a strategic partnership aimed at enhancing drug safety and recall efficiency in the pharmaceutical industry.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

New research published in Science Advances by The Feinstein Institutes for Medical Research scientists shows that activation of the vagus nerve triggers the spleen, thereby regulating the production of antibodies.